People with lower levels of an antiviral antibody as well as those with lung disease take longer to clear COVID-19 symptoms, say Stanford Medicine researchers.

Levels of a stringy, spongy substance soar in the sputum of COVID-19 patients requiring intubation, accounting for at least some of their breathing trouble. Development of an off-patent drug may prevent it.

Stanford Medicine now provides a test for the mpox virus. Rapid identification of infected people will help combat the virus’s spread and facilitate patient care.

Using a method they developed for stem cell transplants, a Stanford team has enabled children with immune disorders to receive a new immune system and a matching kidney from a parent.

Stanford Medicine’s SyneRx will develop drugs to fight viral pathogens with high pandemic potential, including the one that causes COVID-19.

Using machine learning, researchers from Stanford Medicine and their collaborators found specific genetic signals in people who develop severe coronavirus infection.

Stanford Medicine researchers and colleagues found that as nations industrialize, a species of bacteria critical in the early development of infant gut microbiomes fades away.

The Stanford immunologist’s research on how our immune cells recognize pathogens — and what happens when this process goes wrong — paved the way to modern immunology.

Stanford researchers modified anti-cancer CAR-T cells so they can be controlled with an oral drug. The modified cells are safer, more potent and more active against solid tumors in mice.

Monack, whose research focuses on interactions between microbial pathogens and the immune system during infections, succeeds David Schneider.